Company Filing History:
1 out of 3,223 
1 out of 21 Years Active: 2020
Title: The Innovative Journey of Xiaokai Li: A Pioneer in TDO2 Inhibition
Introduction: Xiaokai Li, a notable inventor based in Ames, Iowa, has made significant contributions to the field of pharmaceutical sciences. With a focus on inhibitors of tryptophan 2, 3 dioxygenase (TDO2), his work is pivotal in addressing various medical conditions, including cancer treatment and immunosuppression.
Latest Patents: Li holds a patent for TDO2 Inhibitors, which provides pharmaceutical compositions aimed at modulating the activity of TDO2. This invention is particularly valuable for treating immunosuppression and enhancing the effectiveness of anti-cancer therapies. It addresses conditions that benefit from the inhibition of tryptophan degradation and aims to treat tumor-specific immunosuppression associated with cancer.
Career Highlights: Xiaokai Li has amassed a wealth of experience working with prominent companies in the biotech sector. He has contributed to the success of Genentech, Inc. and Newlink Genetics Corporation, where his expertise in innovation and invention has been invaluable. His work at these organizations reflects his commitment to advancing medical science and improving therapeutic options.
Collaborations: Throughout his career, Li has collaborated with some distinguished professionals in the field. Notable coworkers include Xingyu Lin and Po-Wai Yuen, with whom he has shared ideas and innovations, further enhancing the landscape of pharmaceutical research and development.
Conclusion: Xiaokai Li's impact on the field of pharmaceutical inventions underscores the importance of innovative research in tackling complex medical challenges. His contributions, particularly in the realm of TDO2 inhibition, highlight his role as an influential inventor and a valuable asset to the scientific community. As he continues his work, the potential for new advancements in cancer treatment and immunology remains promising.